Search
![Ascidian Therapeutics' CEO discusses today's collaboration with Roche on the company's RNA exon editing technology for neurological conditions](https://static.wixstatic.com/media/08e71b_3d2be3d2da0d41fb97c513b5ec873fd8~mv2.png/v1/fill/w_326,h_245,fp_0.50_0.50,q_95,enc_auto/08e71b_3d2be3d2da0d41fb97c513b5ec873fd8~mv2.webp)
- Jun 18
Ascidian Therapeutics' CEO discusses today's collaboration with Roche on the company's RNA exon editing technology for neurological conditions
Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA...
![Ascidian presented NHP and human retinal explant data at #ASGCT2024 suggesting proof of concept for its RNA exon editing approach](https://static.wixstatic.com/media/08e71b_5bd96545ae27432ba4cdad613f91286f~mv2.png/v1/fill/w_326,h_245,fp_0.50_0.50,q_95,enc_auto/08e71b_5bd96545ae27432ba4cdad613f91286f~mv2.webp)
- May 9
Ascidian presented NHP and human retinal explant data at #ASGCT2024 suggesting proof of concept for its RNA exon editing approach
Head of research Robert Bell described the preclinical data in a Stargardt disease model that has led to an IND acceptance for this...
![The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease](https://static.wixstatic.com/media/08e71b_bf0cc179e40842e6a57b05973f6c9c35~mv2.png/v1/fill/w_326,h_245,fp_0.50_0.50,q_95,enc_auto/08e71b_bf0cc179e40842e6a57b05973f6c9c35~mv2.webp)
- Jan 29
The Science Behind the News: Ascidian Therapeutics' IND is cleared for an RNA exon editing program against Stargardt disease
Ascidian Interim President & CEO Mike Ehlers explains the scientific concept of RNA exon editing